Neupogen is a medication that has been used effectively for cancer patients to boost the growth of the white blood cells, making patients less vulnerable to infections, it is expected to assist patients who have bone marrow damage from very high dosages of radiation in much the same way. NEUPOGEN is the Amgen Inc. trademark for Filgrastim which has been picked as the name for recombinant methionyl human granulocyte colony-stimulating variable. NEUPOGEN is a 175 amino acid protein manufactured by recombinant DNA technology. 1 NEUPOGEN is generated by Escherichia coli microorganisms into which has been placed the human granulocyte colony-stimulating aspect gene. NEUPOGEN has a molecular weight of 18 800 daltons. The protein has an amino acid series that corresponds the natural sequence forecasted from human DNA series evaluation besides the addition of an N-terminal methionine needed for expression in E coli. Due to the fact that NEUPOGEN is generated in E coli the product is nonglycosylated and hence varies from G-CSF isolated from a human cell. NEUPOGEN is a sterilized clear colorless preservative-free liquid for parenteral administration containing Filgrastim at a specific task of 1. 0. 6 x 108 U/mg. The item is available in single use vials and prefilled syringes. The single use vials consist of either 300 mcg or 480 mcg Filgrastim at a fill volume of 1. 0 mL or 1. 6 mL, specifically. The single use prefilled syringes have either 300 mcg or 480 mcg Filgrastim at a fill volume of 0. 5 mL or 0. 8 mL, specifically. See table below for item make-up of each solitary use vial or prefilled syringe. 300 mcg/. 480 mcg/. 300 mcg/. 480 mcg/.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.